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Abstract
Aims: Glycoprotein VI (GPVI) is a key platelet receptor which mediates plaque-induced platelet activation and consecutive
atherothrombosis, but GPVI is also involved in platelet-mediated atheroprogression. Therefore, interference in GPVI-
mediated platelet activation has the potential to combine short-term and long-term beneficial effects, specificity and safety
especially regarding bleeding complications.
Methods and Results: We investigated the effects of the soluble dimeric GPVI receptor fusion protein, Revacept, an
antagonist of collagen-mediated platelet activation, in an animal model of atherosclerosis: twenty week old rabbits, which
had been fed on a cholesterol-rich diet for 8 weeks, received Revacept (8 mg/kg) or control twice weekly for 4 weeks.
Pharmacokinetics indicated a slight accumulation of the drug in the serum after repeated dosing of Revacept for 3 weeks. A
significant improvement of endothelial dysfunction after 0.06 and 0.6 mg/min acetylcholine and a significant decrease of
vessel wall thickening were found after Revacept treatment. Accordingly, aortic vessel weight was reduced, and plaque
sizes, macrophage and T-cell invasion tended to be reduced in histological evaluations. Bleeding time was determined after
tail clipping in mice. Revacept alone or in combination with widely used anti-platelet drugs revealed a high safety margin
with no prolongation of bleeding times.
Conclusion: Repeated doses of Revacept led to a significant improvement of endothelial dysfunction and vascular
morphology in atherosclerotic rabbits. Furthermore, no influence of Revacept on bleeding time alone or in combinations
with various anti-platelet drugs was found in mice. Thus, the inhibition of collagen-mediated platelet interaction with the
atherosclerotic endothelium by Revacept exerts beneficial effects on morphology and vascular function in vivo and seems
to have a wide therapeutic window without influencing the bleeding time.
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Introduction
Rupture of atherosclerotic plaques leads to adhesion of
circulating platelets to exposed sub-endothelial matrix proteins
which trigger subsequent platelet activation and aggregation.
Among the macromolecular components of the sub-endothelial
layer, fibrillar collagen is considered to be the most thrombogenic
constituent, as it acts as a strong activator of platelets and supports
platelet adhesion both in vitro and in vivo [1,2].
Among the multitude of different platelet receptors, GPVI – a
,68 kilo Dalton Type I trans-membrane glycoprotein receptor
that interacts with collagen to trigger platelet activation and
aggregation – plays a key role in plaque-mediated thrombus
formation [3]. Moreover, GPVI is also involved in chronic platelet
interaction with the activated atherosclerotic endothelium and in
platelet-mediated progression of atherosclerosis [4,5]. Published
data suggest that platelets might significantly contribute to the
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inflammatory process that promotes atherosclerotic lesion forma-
tion [6,7].
Inhibition of the GPVI pathway by anti-GPVI antibodies
ameliorates atherosclerosis in ApoE 2/2 ablated mice [8].
Another possibility to interfere in the GPVI pathway is the soluble
GPVI receptor Revacept [1]. Revacept is a dimeric recombinant
fusion protein consisting of the Fc part of a human immunoglob-
ulin G (IgG) together with the hinge region and the functional
GPVI domain at the N-terminus (GPVI-Fc) [1]. This novel anti-
platelet tool has been proven beneficial in various animal models
of acute vascular injury [1,9]. Moreover, the safety and efficacy
was demonstrated in a controlled phase I study in man [10].
Human GPVI-Fc/Revacept is thought to act by blocking the
binding sites of platelets at collagen, fibronectin [8,11] and possibly
other vascular ligands, such as von Willebrand factor, and
therefore might interfere with platelets not only in acute plaque
rupture but also during chronic interaction with the activated but
intact atherosclerotic endothelium.
In this study, we therefore aimed to clarify the role of GPVI on
platelet-mediated plaque progression. Moreover, we investigated
the role of the platelet activation inhibitor Revacept as a novel tool
to interfere in platelet-triggered vessel damage by studying the
effects on the functional and morphological consequences of
atherosclerosis. Cholesterol-fed rabbits are a suitable model for the
in vivo investigation of atherosclerosis [8]. Finally, we also
investigated the safety of this novel drug by testing drug interaction
with other established anti-platelet drugs on bleeding time.
Materials and Methods
All animal experiments were approved by the local animal
welfare authority and Ehtics committee at the Regierung von
Oberbayern (Government of Upper Bavaria) in Munich, Ger-
many (reference number 209.1/211-2531.-37/04) and carried out
in accordance to the European Commission guidelines.
Animals
New Zealand White (NZW) rabbits (aged 20 weeks, from Asam,
Kissing, Germany) were used according to international and
national guidelines for animal health. A permission to carry out
animal studies was granted from the local animal safety
supervising authority (study numbers 209.1/211-2531.-37/04).
Standard rabbit chow and water were freely available. For the
induction of atherosclerosis, the animals were fed a cholesterol-
rich diet (1% cholesterol 5% corn oil; Altromin GmbH, Lage,
Germany) from the age of 20 weeks until the end of experiment
(when the animals were aged 28 weeks).
Nine week old male black six mice (C57Bl/6J) were obtained
from Charles River, Sulzfeld, Germany, and used in bleeding
experiments.
Carotid Artery Endothelial Denudation
Under general anaesthesia (Propofol 1%, Fresenius Kabi, Bad
Homburg, Germany), the left femoral artery was prepared, an
embolectomy catheter (3F, Edwards Lifesciences) was introduced
in the right carotid artery and endothelial denudation was carried
out between the second and sixth cervical vertebrae by gently
moving the inflated (with 0.4 ml of air) balloon catheter backwards
and forwards twice. 30 min before damage to the right carotid
artery was induced, the rabbits (n = 69) were given Revacept
(batch 260805), Fc control (batch CP31) or PBS by continuous iv
infusion via the ear vein of 5 ml over a period of 3 min. The doses
used were: 0.2 mg/kg; 0.6 mg/kg; 1 mg/kg; 2 mg/kg; and 3 mg/
kg PR-15; and 2 mg/kg Fc control. Please see Figure 1 (upper
panel) for an overview on the protocol.
Evaluation of the Denudation after Balloon Injury
For investigation of the position and extent of the endothelial
lesion produced by the balloon, rabbits were given Evans Blue
(2%, 1 ml/kg) iv after endothelial denudation, as described
previously (e.g., Ohtsuki K, Hayase M, Akashi K et al., Detection
of MCP-1 receptor expression in experimental atherosclerotic
lesions. Circulation 2001; 104: 203–208). After euthanasia with
pentobarbital iv (60 mg/kg, NarcorenH, Merial GmbH, Ger-
many), paraformaldehyde was administered iv (2% in PBS, for 10
minutes, 100 mm Hg pressure) for tissue fixation. The right and
left common carotid arteries were removed, cleaned of adventitia
and connective tissue, and segments of the arteries (starting 0.6 cm
from the distal end of the brachiocephalic trunk and ending at the
carotid bifurcation 6 cm distal from the starting position) were
opened longitudinally with the endothelium facing up and pinned
flat on a white wax plate.
A digital picture of each prepared vessel was taken with a
Canon EOS 300 camera, and the lesion area was calculated from
the digital picture using computer-assisted image analysis software.
This analysis quantified the blue (damaged) area of the lesion in
pixels and the total area of the complete vessel segment in pixels
(Scion image; Scion Corporation, Frederick, MD, USA). The total
area (expressed as pixels) varied due to different resolutions of the
digital pictures. Therefore, the lesion area was calculated as
percent of the total area. In addition, sections of tissue from both
the right and left carotid arteries were cut, fixed, processed and
stained with haematoxylin and eosin and Elastic van Gieson
staining to evaluate the degree of denudation and depth of the
lesion.
Quantification of Thrombus Formation
Four hours after local or systemic drug administration, the left
and right common carotid arteries were fixed by iv perfusion with
paraformaldehyde (2% in PBS, for 10 min, via a catheter through
the abdominal aorta, 100 mm Hg pressure) and removed. They
were cleaned of adventitia and connective tissue, and segments of
the arteries were opened longitudinally with the endothelium
facing up.
After mounting the segments on slides, the insides of the vessels
were examined macroscopically. Thrombi were easily visible by
their red colour against the white background of the vessel wall. A
digital picture of the prepared vessel was then taken with a Canon
EOS 300 camera and the area covered by thrombi was quantified
from the digital picture using computer-assisted image analysis
software (Scion image; Scion Corporation, Frederick, MD, USA),
which detected the red thrombus area in pixels and the total area
of the complete vessel segment in pixels. The total area was thus
the same in all the arteries analysed. Again, the total area varied
due to the different resolutions of the digital pictures. Therefore,
the area covered by thrombi was calculated as a proportion of the
total area.
Atherosclerosis
16 rabbits were randomly assigned to receive either Revacept or
vehicle control. Blood samples were taken to investigate baseline
and high-cholesterol diet serum cholesterol levels. Eight rabbits
were infused with Revacept (8 mg/kg in 3.33 ml/kg formulation
buffer) intravenously (iv) via the ear vein twice weekly for four
weeks. This dose had been chosen on the basis on prior ex vivo
investigation of foam cells. Eight animals were given formulation
buffer (PBS pH 7.4, 4% mannitol, 1% sucrose), and served as
Revacept in Atherosclerosis
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Figure 1. Study protocols of thrombus size detection after carotis artery lesion (upper panel), and of atherosclerosis in cholesterol-
fed rabbits after eight weeks of drug administration (lower panel).
doi:10.1371/journal.pone.0071193.g001
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Figure 2. Effect of systemic delivery of increasing doses of Revacept in rabbits. Thrombus formation was induced by balloon vascular
injury. The thrombus size was evaluated histologically post mortem and is expressed as % of the total vascular lesion area. The mean 6 SD of n = 8
experiments per group are shown. * indicates significant difference of p,0.05, and ** of p,0.01, versus controls (as determined by ANOVA).
doi:10.1371/journal.pone.0071193.g002
Figure 3. Representative images of thrombi in carotid artery preparations (en face). LC: left carotid artery; RC: right carotid artery.
doi:10.1371/journal.pone.0071193.g003
Revacept in Atherosclerosis
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controls (control group). The pharmacokinetic profiling of
Revacept was carried out on day 1 and 22 of the dosing period.
Please see Figure 1 (lower panel) for an overview on the protocol.
The general condition of the animals was checked daily and
rabbits were weighed weekly before and twice weekly after start of
drug infusions, respectively.
When the animals had reached an age of 28 weeks, endothelial
function was investigated in vivo by vascular ultrasound under
general anaesthesia (Propofol 1%, Fresenius Kabi, Bad Homburg,
Germany). To this end, acetylcholine-induced vasoreactivity, and
vessel wall thickness were determined. Animals were sacrificed and
the heart, the thoracic and abdominal aorta and both common
carotid arteries were removed and stored at 280uC until required
for histological examinations. The investigators were blinded
during the complete in-life part of the study as well as during the
histological evaluation post mortem.
Figure 4. Pharmacokinetic profile of Revacept in rabbits (A) on the first day of dosing (after 4 weeks of high cholesterol feeding),
(B) after the last dosing of the twice weekly dosing period four weeks later. The graphs show single animal and mean values of the
Revacept group.
doi:10.1371/journal.pone.0071193.g004
Revacept in Atherosclerosis
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Determination of Serum Cholesterol Levels
Serum cholesterol was determined before and in week 5 and 8
of cholesterol-rich diet with a commercial photometric method
(Synlab vet, Augsburg, Germany).
Analytical Methods for Assessment of PK Profiles
Revacept concentrations were determined according to the
manufacturer’s instructions using a commercial ELISA Kit
(Immuno-Tek, ZMC Cat. No. 0801182).
Calculation and Interpretation of the PK Results
Revacept pharmacokinetics were calculated with a non-
compartmental analysis (NCA) using PCModfit (version 3.00) for
WindowsH running with Excel 2003 (version 11.8). Half-life,
terminal elimination rate constant (lz) and area under the
concentration-time curve to the last time point (AUC0-t) and
area to infinity (AUC0-‘) was estimated using AUC0-t were
calculated.
Investigation of Endothelial Function in Atherosclerosis
At an animal age of 24 weeks and 28 weeks, the endothelial
function was investigated under general anaesthesia (Propofol 1%,
Fresenius Kabi, Bad Homburg, Germany) iv. Monitoring of mean
heart rate (HR), end-tidal CO2 (EtCO2) and arterial oxygen
saturation (SpO2) was carried out using a Datex device (Datex
Ohmeda S/5, Type F-CM1.00, Helsinki, Finland, pressure
transducer: Hellige Type 4-327-I). Vascular ultrasound was
carried out over the right ACC using a 10 MHz linear transducer
(FLA 10 MHz 1A, GE Vingmed, Horten, Norway) in conjunction
with a Vingmed ultrasound system (A/S System FIVE/REM, GE,
Horten, Norway). Endothelial function was investigated by
continuous infusion of increasing concentrations of acetylcholine
(Acetylcholine chloride, Sigma-Aldrich Chemie GmbH, Stein-
heim, Germany). A group of six healthy New Zealand White
rabbits which had been kept at regular chow, and were also aged
28 weeks, was additionally compared to the cholesterol-fed rabbits.
Vessel luminal diameter at maximum vessel dilation and vessel
wall thickness were determined before and after increasing doses
of acetylcholine (0.006 mg/min, 0.06 mg/min and 0.6 mg/min).
Macroscopic Assessment of Atherosclerosis
After sacrifice of the animals, the aortae (including the
brachiocephalic trunk) and the left and right common carotid
arteries were carefully removed and frozen in liquid nitrogen. The
vessels were macroscopically prepared for ‘‘en face’’ evaluation of
plaque extension. After overnight post-fixation in 4% formalin, the
arteries were stained with Sudan red. The endothelium facing up
photographs with a Canon EOS 300 camera were taken. Digital
pictures were analysed (Scion image; Scion Corporation, Freder-
ick, MD, USA), and relative plaque area was calculated in percent
of the total vessel area.
Histological Evaluation of Intima and Media Area in
Brachiocephalic Trunk
Vessels were freeze-cut in sequential 6-mm sections and standard
Haematoxylin and eosin (HE) and van Gieson elastic (VG) staining
were performed (HT25, Sigma Diagnostics, Louis, UpSA).
Digital images were obtained and the intima and media areas
were assessed by computer-assisted image analysis (as described
above). For immunohistochemical analysis, the sections were post-
fixed with acetone and counterstained with Harris haematoxylin.
As primary antibodies, mouse monoclonal anti-rabbit RAM 11
antibody (DAKO, Hamburg, Germany, used at a dilution of 1:50)
were used for macrophages, mouse monoclonal anti-rabbit CD 43
(Serotec, used at 0.33 mg/ml) for T-cells. Biotinylated anti-mouse
(DAKO, Hamburg, Germany) antibodies were used as secondary
antibodies, at a titer of 1:300, as recommended by the
manufacturer. Antibody binding was visualised by incubation
with the substrate 3939-diaminobenzidine (DAB).
Quantification of the Cell Density by
Immunohistochemistry
Serial sections of 5 mm were cut every 75 mm along the
brachiocephalic artery and every 80 mm along the 230-mm
segment of the aortic roots. The first tissue section of every
segment was stained with hematoxylin/eosin. Adjacent sections
were stained with oil red O, Sirius red, Movat’s pentachrome, and
Elastic van Gieson and immunostained for the visualization.
Macrophage and T-cell numbers were determined by counting
blue nuclei in positively stained cells within lesions. The
investigator was blinded during this histological evaluation.The
relative content of the immune cells was then calculated by
forming the ratio of the number of specific cells and the plaque
area, evaluated in adjacent van Gieson elastic stained sections.
The analysis of lesions was performed in a blinded fashion.
Bleeding Time Measurement in Rabbits
For investigation of primary bleeding time in atherosclerotic
rabbits, animals were treated with propofol (1%, 5–8 mg/kg iv
with continuing low-dose administration), until deep anaesthesia
was reached. Then, a standardized incision with a length of 5 mm
Figure 5. Serum cholesterol levels of the Revacept group and the control group before, 4 and 8 weeks after feeding a high-
cholesterol diet (means ± SEM).
doi:10.1371/journal.pone.0071193.g005
Revacept in Atherosclerosis
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and a depth of 1 mm was placed in the right ears of rabbits with a
number 11 surgical blade. The ear was then immersed in a beaker
containing saline warmed around 38.5uC, and duration of
bleeding was measured. Revacept (2 mg/kg body weight) or
vehicle were given 30 minutes prior to measurement by iv bolus
injection via a needle which had been placed in a contralateral ear
vein.
Bleeding Time Measurement in Mice and the Influence of
Drug Interactions on the Safety of Revacept
For investigation of the bleeding time, the tail transsection
method was used which is a well-established technique in mice.
Except for clopidogrel, acetyl salicylic acid in combination with
dipyridamol, all drugs and saline were administered intravenously
to conscious animals (restrained in an injection chamber) in a
volume of 100 ml. The tails were transsected at the time of the
Figure 6. Endothelial dysfunction and arterial wall thickness was assessed in rabbits after 8 weeks of high cholesterol diet. (a)
Vascular ultrasound of the right common artery: The bars show increases of luminal diameter of the right common carotid artery [%] compared to
baseline after infusion of three doses of acetylcholine in the Revacept and control groups. (b) Wall thickness of the right common carotid artery [mm]
in rabbits. The mean6 SEM of 8 animals are shown. * indicates significant difference of p,0.05 versus cholesterol-fed, atherosclerotic control rabbits,
and ** p,0.01 versus healthy rabbits (ANOVA).
doi:10.1371/journal.pone.0071193.g006
Revacept in Atherosclerosis
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anticipated approximate Cmax or maximal anti-coagulative/anti-
platelet effect in mice: Revacept 30 min, aspirin 60 min and
heparin 10 min. Clopidogrel, dissolved in sodium chloride with a
volume of 200 ml, was given orally by gavage under short-term
anaesthesia with isoflurane 120 minutes before tail transsection.
For determination of bleeding time, the mice were anaesthetised
with medetomidine (DomitorH 500 mg/kg), midazolam (Dormi-
Figure 7. Macroscopic and histological assessment of atherosclerosis in cholesterol-fed rabbits. (a) Plaque size [%] was determined in
macroscopic en face preparations after sudan red staining of the common carotid arteries. The relative lesion area was expressed as percentage of
the total vessel area of the common carotid artery. (b) Vessel wet weight to body weight ratio was determined. The mean 6 SEM of 8 animals are
shown. * indicates significant difference of p,0.05 versus cholesterol-fed atherosclerotic control rabbits.
doi:10.1371/journal.pone.0071193.g007
Revacept in Atherosclerosis
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cumH 5 mg/kg) and fentanyl (Fentanyl B. Braun 50 mg/kg)
intraperitoneally 10 min prior to tail transsection. The distal
2 mm of the animals tail was sectioned with a scalpel blade and
the tail immersed in warm buffer solution (PBS). Bleeding time was
recorded immediately following transection and was continued
until blood ceased to flow from the tip of the tail without restarting
within 30 seconds.
The effect of Revacept (2 mg/kg BW) on bleeding time was
compared to animals receiving various doses of clopidogrel, acetyl
salicylic acid (Aspirin, ASA) dipyridamol and heparin, and
combinations of those. The doses of the comparator drugs
corresponded to the maximum doses approved for therapeutic
use in humans, and were calculated for use in mice on a per body
weight basis. The dose of ASA (14 mg/kg BW) is comparable to
that which is given to humans in a 70–75 kg patient. Clopidogrel
1 mg/kg BW corresponds to the recommended human dose of
75 mg daily, while 5 and 10 mg/kg BW correspond to the loading
doses of clopidogrel (300 and 600 mg).
Additionally, the daily therapeutic doses of Aggrenox (ASA
50 in combination with dipyridamole 400 mg) in combination
with acetyl salicylic acid (100 mg) were tested after p.o.
applications in mice. The body weight doses for acetyl salicylic
acid in combination with dipyridamole of 2 mg/kg BW and of
5.3 mg/kg BW were calculated on the basis of a 75 kg patient.
Statistical Analysis
The results were tested for Gaussian distribution using the
Kolmogorow-Smirnov test. If this test showed normal distribution
of the values, an ANOVA followed by post-hoc Bonferronis
analysis was used to compare groups. Where appropriate, a t-test
for independent samples was used. P-values ,0.05 were consid-
ered statistically significant.
Results
Endothelial Lesion after Balloon Injury
Reproducible thrombus formation developed in all experiments
at the sites of Fogarty balloon catheter-induced injury of the right
carotid artery of rabbits with little variability between experiments.
The areas of endothelial injury were confirmed by Evans Blue
staining. By semi-quantitative computer-assisted image analysis,
7666% of the vessel area of the right common carotid artery that
was digitally analysed showed a lesion of the endothelium. Staining
with haematoxylin and eosin and Elastic van Gieson confirmed
that the internal tunica elastica was intact and that the lesion was
limited to the endothelium. Bleeding and coagulation within the
media or swelling of the vessel wall that could have affected blood
flow could be excluded.
Figure 8. Representative images of plaque extensions in artery sections. LC: left carotid artery; RC: right carotid artery, Thor A: thoracic
aorta, Abd A: abdominal aorta.
doi:10.1371/journal.pone.0071193.g008
Revacept in Atherosclerosis
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Effect of Revacept on Thrombus Formation after Balloon
Injury
Single administration of Revacept 30 min prior to denudation
at doses of 1 mg/kg, 2 mg/kg and 3 mg/kg iv produced a
statistically significant reduction in thrombus formation compared
to the group treated with the Fc control/PBS (see Figure 2).
Representative photographic images are shown in Figure 3. The
lower doses of Revacept also reduced thrombus formation.
However, these differences did not reach statistical significance.
The dose range used in this study was already used in several
previous studies, and shown to be effective [1].
Pharmacokinetic Profile of Revacept
After repeated IV administration of Revacept (8 mg/kg) in
another group of rabbits, the mean Cmax values were 283.1 mg/
mL on the first day and 320.4 mg/mL on the 22nd day,
respectively, indicating only a slight accumulation of the drug in
the serum after repeated dosing of Revacept (please see Figures 4
A and B). The mean t1/2 of Revacept was 25.6 h on the first day of
dosing and 31.9 h on the 22nd day after repeated doses. Dosing of
3 or 2 mg/kg BW Revacept had previously resulted in similar
curve shapes, and proportionately lower Cmax values. The
variability of the PK assay was low with a CV between 11.2 to
27.8% at consecutive time points. No drug was detected in the
serum samples of the control animal.
Figure 9. The inflammation in the arterial wall was assessed by immune-histology in carotid artery sections of cholesterol fed
rabbits. (a) The density of macrophages was determined using specific anti-RAM antibodies.(b) The density of T-lymphatic cells was determined with
specific anti CD 4 antibodies. The mean 6 SEM of 8 animals are shown.
doi:10.1371/journal.pone.0071193.g009
Revacept in Atherosclerosis
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Figure 10. Representative immuno-histological images of macrophage and T lymphocyte stains of carotid artery sections.
doi:10.1371/journal.pone.0071193.g010
Revacept in Atherosclerosis
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Serum Cholesterol Levels and Body Weight
In the rabbits which were fed with high fat chow for 8 weeks,
serum cholesterol levels increased consistently - no significant
differences between the Revacept-dosed group and the control
animals occurred (please see Figure 5). Mean body weights did not
differ significantly between Revacept-treated animals and control
animals during the investigation period.
Acetylcholine-induced Vasoreactivity
In the cholesterol-fed rabbits, induction of vasodilation was
determined as a measure of endothelial function by ultrasound-
detected change in vessel diameter at the end of the experiment. A
significant improvement of endothelial function was measured in
Revacept-treated hypercholesterolemic animals compared to
control animals. Vasoreactivity was significantly improved during
acetylcholine infusion of 0.06 mg/min and 0.6 mg/min in animals
after 4 weeks of treatment with Revacept twice weekly, when
compared to vehicle-treated control animals (see Figure 6a).
Thickness of the Vessel Wall
Additionally, a significant reduction of the vascular wall
thickness was observed in Revacept-treated hypercholesterolemic
animals compared to vehicle-treated control atherosclerotic
animals. Additionally, the cholesterol-fed Revacept group even
showed no significant difference compared to healthy animals
without treatment (see Figure 6b).
Plaque Size Measurements in en Face Preparations
(Macroscopic Evaluation)
In Revacept-treated hypercholesterolemic animals, plaque size
tended to be reduced in both common carotid arteries and in the
abdominal aorta, although these differences did not reach
statistical significance (see Figure 7a). Representative images are
shown in Figure 8. Additionally, Revacept-treated hypercholes-
terolemic rabbits showed a significant reduction of the vessel
weights of their aortae compared to controls (see Figure 7b).
Immunostaining for Determination of the Density of
Macrophages and Lymphatic Cells in the Vessel Wall
Intima
The density of macrophages and lymphatic T-cells was
statistically not different from controls - it tended to be reduced
in the intima of the brachiocephalic trunk in Revacept-treated
hypercholesterolemic animals compared to controls (see Figures 9a
and 9b). Representative immuno-histological images are shown in
Figure 10.
Bleeding Times in Rabbits
30 minutes after intravenous administration of 2 mg/kg
Revacept, bleeding time was 173661 seconds, whereas it was
161656 seconds after IV administration of vehicle only (n = 8
animals for each condition). There was no significant difference
between the groups.
Figure 11. Tail bleeding time was assessed after tail clipping in mice. Revacept was investigated alone and in combination with existing
drugs. The means6 SEM of n = 8 animals per group are demonstrated. Stars (*) indicate significant differences, p,0.05 versus native, untreated mice,
or vs. mice which were only treated with 2 mg/kg Revacept (ANOVA).
doi:10.1371/journal.pone.0071193.g011
Revacept in Atherosclerosis
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Measurement of Bleeding Time in Mice
Bleeding times were also measured in mice by a standardized
tail clipping protocol. These extended measurements could not be
all done in rabbits, since it would have meant too many
experiments in that species.
A marked prolongation of bleeding time was induced after
administration of established drugs such as Aspirin (14 mg/kg
body weight IV), Heparin (100 IU IV), or clopidogrel (1 mg/kg
body weight; 5 mg/kg body weight or 10 mg/kg body weight p.o)
in mice. These doses are equivalent to standard or emergency
doses with respect to per kg bodyweight doses used in patients with
acute coronary syndromes. The doses correspond to 1000 mg
Aspirin, 600 mg Clopidogrel, or 7500 IU Heparin per patient.
Combining these drugs with Revacept (2 mg/kg) which corre-
sponds to a dose of 160 mg per patient had no additional effect on
bleeding times (see Figure 11).
Discussion
In this study, we investigated the effects of an inhibition of
GPVI-mediated platelet activation by Revacept on acute throm-
bus formation and on the progression of atherosclerosis in rabbits.
Moreover, we intended to characterise the safety of Revacept with
specific focus on bleeding complications in combination with other
widely used anti-thrombotic drugs. Revacept dose-dependently
reduced thrombus formation after endothelial injury. A significant
improvement of endothelial dysfunction and vessel wall thickness
was detected by in vivo vascular ultrasound after 4 weeks of
Revacept in rabbits on high-fat diet. Finally, Revacept did not
worsen the bleeding time in mice when applied in combination
with widely used anti-thrombotic drugs in relevant doses.
It was demonstrated by various investigations that a high
percentage of patients with acute coronary syndromes (ACS) had
multiple ruptured plaques that induced atherothrombosis. More-
over, endothelial dysfunction was strongly associated with
inflammation during advanced platelet aggregation and thrombus
formation [12]. An increase in endothelial production of pro-
coagulatory agents results in a thrombogenic vascular environ-
ment leading to thrombus formation by ruptured or erosive
plaques [13]. It was a major finding of this study that treatment of
atherosclerotic rabbits with Revacept also had a profound effect on
the acetylcholine-induced endothelial function as determined by
vascular ultrasound. Earlier studies had shown that Revacept
prevents platelet adhesion [1] and this leads to a decrease of the
inflammatory response in the endothelium [13]. Thus, the
improvement of the endothelial function by Revacept is most
likely due to a direct anti-platelet effect and subsequent to
reduction of the inflammatory response by activated platelets. In
earlier studies of our group, we showed that atheroprogression in
two different atherosclerosis models was inhibited in the presence
of Revacept [8,14]. In these studies, both repeated administration
of recombinant Revacept in ApoE 2/2 mice and gene transfer of
GPVI-Fc to the carotid artery in cholesterol-fed rabbits were
performed. Both interventions resulted in a notable decrease of
atheroprogression in the arteries of either ApoE2/2 mice [14] or
cholesterol-fed rabbits with a significant reduction of plaque
extension [8]. However, the expression of GPVI-Fc caused by an
attenuated adenovirus is rather unfavorable due to induction of
inflammation per se.
In vivo administration of a monoclonal anti-GPVI-antibody
(JAQ1) in ApoE (2/2) mice after vascular injury reduced
aggregation and adhesion of platelets at the arterial vessel wall
[2]. Moreover, chronic administration of JAQ1 also markedly
reduced atheroprogression in ApoE 2/2 mice [14]. Thus, GPVI
seems to be a necessary regulator of platelet activation both in
acute and chronic vascular syndromes. On the other hand,
treatment with anti-GPVI-antibodies caused complete internali-
zation and depletion of GPVI on platelets [2]. Thereby, these anti-
GPVI antibodies, such as JAQ1, induced a strong and transient
thrombocytopenia and significantly prolonged increase of the
bleeding time [15]. In a controlled phase I study, we recently
demonstrated in healthy human volunteers that Revacept had no
pro-arrhythmic effect. Systolic blood pressure values, heart rate
and ECG were all within the normal range after administration of
Revacept. There was also no influence on the bleeding time, nor
influence on the general haemostasis as assessed by partial
thromboplastin time or INR in the subjects [10]. In this study
we additionally demonstrate that Revacept did not prolong
bleeding time after tail clipping in mice even when applied in
combination with the most common used anti-thrombotic drugs.
In contrast, the use of of 1000 mg aspirin or 600 mg clopidogrel
caused excessive prolongation of bleeding time. The combination
with Revacept with either drug, however, had no additional effect.
Concerning the data obtained with clopidogrel, one publication
showed prolongation of bleeding time after double dosing of
3 mg/kg bw clopidogrel over 2 days in anaesthesized mice [16].
In our study, single dosings were compared, so that a lack of
prolongation after 5 mg/kg seems plausible. Accordingly, thigh
bleeding time was not altered after single dosing of 5 mg/kg
clopidogrel in pigs, and moderately increased after 10 mg/kg [17].
Thus Revacept seems to possess unique features as an effective
anti-platelet drug without the inherent side effect of increased
bleeding.
The reason for using rabbits was to show that Revacept is not
only an effective drug in the treatment of atherosclerosis in mice
[14]. The use of another animal model to demonstrate efficacy can
avoid drawing premature conclusions for the further drug
development. Particularly, it was shown that other anti-athero-
sclerotic drugs such as statins fail to show efficacy in ApoE2/2
mice [18]. In this manuscript, we show that Revacept is effective in
reducing the morphological changes and in particular the
endothelial dysfunction in two independent in vivo atherosclerosis
models [8]. In accordance with previous studies it prevents platelet
thrombus formation at vascular lesions [1]. Thus Revacept seems
to impact on the known ligands in the atherosclerotic plaque after
plaque rupture (i.e. collagen) and further ligands present on the
activated atherosclerotic endothelium which shows no obvious
lesions (i.e. fibronectin [8]).
Limitations of the study: Mouse tail bleeding times were
investigated for some measurements of drug combinations in the
current study, because the use of such a relevant animal number in
other animal species would not have been compatible with local
Ethics Committees regulations. Investigation of this parameter in
mice cannot entirely predict bleeding in humans, although it is
often used to obtain a first idea on the respective bleeding risk.
Revacept therefore promises to be a useful efficient drug to
interrupt platelet-triggered short-term thrombosis, but also long-
term endothelial dysfunction and plaque progression in athero-
sclerosis, and does not incur the risk of bleeding complications as
conventional anti-platelets drugs do.
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